TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2016 Apr 5

PMID 27043163

Citations 69

Authors

Christine C Krieger

Robert F Place

Carmine Bevilacqua

Bernice Marcus-Samuels

Brent S Abel

Monica C Skarulis

George J Kahaly

Susanne Neumann

Marvin C Gershengorn

Affiliations

Soon will be listed here.

Abstract

Context: The TSH receptor (TSHR) is considered the main target of stimulatory autoantibodies in the pathogenesis of Graves' ophthalmopathy (GO); however, it has been suggested that stimulatory IGF-1 receptor (IGF-1R) autoantibodies also play a role.

Objective: We previously demonstrated that a monoclonal stimulatory TSHR antibody, M22, activates TSHR/IGF-1R cross talk in orbital fibroblasts/preadipocytes obtained from patients with GO (GO fibroblasts [GOFs]). We show that cross talk between TSHR and IGF-1R, not direct IGF-1R activation, is involved in the mediation of GO pathogenesis stimulated by Graves' autoantibodies.

Design/setting/participants: Immunoglobulins were purified from the sera of 57 GO patients (GO-Igs) and tested for their ability to activate TSHR and/or IGF-1R directly and TSHR/IGF-1R cross talk in primary cultures of GOFs. Cells were treated with M22 or GO-Igs with or without IGF-1R inhibitory antibodies or linsitinib, an IGF-1R kinase inhibitor.

Main Outcome Measures: Hyaluronan (hyaluronic acid [HA]) secretion was measured as a major biological response for GOF stimulation. IGF-1R autophosphorylation was used as a measure of direct IGF-1R activation. TSHR activation was determined through cAMP production.

Results: A total of 42 out of 57 GO-Ig samples stimulated HA secretion. None of the GO-Ig samples exhibited evidence for IGF-1R autophosphorylation. Both anti-IGF-1R antibodies completely inhibited IGF-1 stimulation of HA secretion. By contrast, only 1 IGF-1R antibody partially blocked HA secretion stimulated by M22 or GO-Igs in a manner similar to linsitinib, whereas the other IGF-1R antibody had no effect on M22 or GO-Ig stimulation. These findings show that the IGF-1R is involved in GO-Igs stimulation of HA secretion without direct activation of IGF-1R.

Conclusions: IGF-1R activation by GO-Igs occurs via TSHR/IGF-1R cross talk rather than direct binding to IGF-1R, and this cross talk is important in the pathogenesis of GO.

Citing Articles

IGF1R/ARRB1 Mediated Regulation of ERK and cAMP Pathways in Response to Aβ Unfolds Novel Therapeutic Avenue in Alzheimer's Disease.

Sengupta P, Mukhopadhyay D Mol Neurobiol. 2025; .

PMID: 39969678 DOI: 10.1007/s12035-025-04735-6.

Effects of linsitinib on M22 and IGF:1-treated 3D spheroids of human orbital fibroblasts.

Hikage F, Suzuki M, Sato T, Umetsu A, Ogawa T, Nishikiori N Sci Rep. 2025; 15(1):384.

PMID: 39747159 PMC: 11697574. DOI: 10.1038/s41598-024-83193-x.

Linsitinib inhibits IGF-1-induced cell proliferation and hyaluronic acid secretion by suppressing PI3K/Akt and ERK pathway in orbital fibroblasts from patients with thyroid-associated ophthalmopathy.

Lee J, Lee S, Yang S, Paik J PLoS One. 2024; 19(12):e0311093.

PMID: 39693285 PMC: 11654993. DOI: 10.1371/journal.pone.0311093.

Teprotumumab versus intravenous methylprednisolone in thyroid eye disease: A systematic review.

Mehmood F, Rizvi S, Alam S, Ansari B Oman J Ophthalmol. 2024; 17(3):313-319.

PMID: 39651498 PMC: 11620316. DOI: 10.4103/ojo.ojo_308_23.

Role of genetics and epigenetics in Graves' orbitopathy.

Marino M, Rotondo Dottore G, Menconi F, Comi S, Cosentino G, Rocchi R Eur Thyroid J. 2024; 13(6).

PMID: 39378053 PMC: 11623286. DOI: 10.1530/ETJ-24-0179.

References

Smith T, Hoa N . Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004; 89(10):5076-80. DOI: 10.1210/jc.2004-0716. View

van Zeijl C, Fliers E, van Koppen C, Surovtseva O, de Gooyer M, Mourits M . Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients. Thyroid. 2010; 20(5):535-44. DOI: 10.1089/thy.2009.0447. View

Tramontano D, Cushing G, Moses A, Ingbar S . Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG. Endocrinology. 1986; 119(2):940-2. DOI: 10.1210/endo-119-2-940. View

Varewijck A, Boelen A, Lamberts S, Fliers E, Hofland L, Wiersinga W . Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 2013; 98(2):769-76. DOI: 10.1210/jc.2012-2270. View

Evanko S, Potter-Perigo S, Johnson P, Wight T . Organization of hyaluronan and versican in the extracellular matrix of human fibroblasts treated with the viral mimetic poly I:C. J Histochem Cytochem. 2009; 57(11):1041-60. PMC: 2762883. DOI: 10.1369/jhc.2009.953802. View

Suzuki N, Yoshihara A, Yoshimura Noh J, Kozaki A, Inoue T, Sugino K . Pathological Findings of the Thyroid Tissue in a Patient with Euthyroid Graves' Disease. Intern Med. 2015; 54(22):2881-4. DOI: 10.2169/internalmedicine.54.3346. View

Delcourt N, Bockaert J, Marin P . GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol Sci. 2007; 28(12):602-7. DOI: 10.1016/j.tips.2007.09.007. View

Chen H, Shan S, Mester T, Wei Y, Douglas R . TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist. PLoS One. 2015; 10(6):e0130322. PMC: 4472723. DOI: 10.1371/journal.pone.0130322. View

van Zeijl C, Fliers E, van Koppen C, Surovtseva O, de Gooyer M, Mourits M . Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways. Thyroid. 2010; 21(2):169-76. DOI: 10.1089/thy.2010.0123. View

10.

Girnita L, Shenoy S, Sehat B, Vasilcanu R, Vasilcanu D, Girnita A . Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J Biol Chem. 2007; 282(15):11329-38. DOI: 10.1074/jbc.M611526200. View

11.

Weightman D, Perros P, Sherif I, Kendall-Taylor P . Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 1993; 16(4):251-7. DOI: 10.3109/08916939309014643. View

12.

Pyne N, Pyne S . Receptor tyrosine kinase-G-protein-coupled receptor signalling platforms: out of the shadow?. Trends Pharmacol Sci. 2011; 32(8):443-50. DOI: 10.1016/j.tips.2011.04.002. View

13.

Minich W, Dehina N, Welsink T, Schwiebert C, Morgenthaler N, Kohrle J . Autoantibodies to the IGF1 receptor in Graves' orbitopathy. J Clin Endocrinol Metab. 2012; 98(2):752-60. DOI: 10.1210/jc.2012-1771. View

14.

Pritchard J, Han R, Horst N, Cruikshank W, Smith T . Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003; 170(12):6348-54. DOI: 10.4049/jimmunol.170.12.6348. View

15.

Morshed S, Latif R, Davies T . Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology. 2008; 150(1):519-29. PMC: 2630889. DOI: 10.1210/en.2008-0878. View

16.

Bahn R . Graves' ophthalmopathy. N Engl J Med. 2010; 362(8):726-38. PMC: 3902010. DOI: 10.1056/NEJMra0905750. View

17.

Lytton S, Ponto K, Kanitz M, Matheis N, Kohn L, Kahaly G . A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J Clin Endocrinol Metab. 2010; 95(5):2123-31. DOI: 10.1210/jc.2009-2470. View

18.

Mukasa K, Yoshimura Noh J, Kouzaki A, Ohye H, Kunii Y, Watanabe N . TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients. Endocr J. 2015; 63(2):151-7. DOI: 10.1507/endocrj.EJ15-0137. View

19.

Rapoport B, McLachlan S . The thyrotropin receptor in Graves' disease. Thyroid. 2007; 17(10):911-22. DOI: 10.1089/thy.2007.0170. View

20.

Smith T, Hegedus L, Douglas R . Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012; 26(3):291-302. PMC: 3712747. DOI: 10.1016/j.beem.2011.10.002. View